Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FASST: Lanifibranor in Diffuse Cutaneous Systemic Sclerosis
NCT02503644Phase 2Completed
- Sponsor
- Inventiva
- Start
- Oct 2015
- Primary completion
- Oct 2018
- Modality
- Small Molecules
- Countries
- 10
01
Overview
Phase 2, randomised, double-blind trial of lanifibranor in diffuse cutaneous systemic sclerosis (dcSSc) (3 arms), sponsored by Inventiva. Primary endpoint: Modified Rodnan Skin Score at 48 weeks. Started Oct 2015; status: completed.
02
Drugs
lanifibranor
03
Conditions
diffuse cutaneous systemic sclerosis (dcSSc)
Beyond the preview
Go deeper on NCT02503644.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02503644.